#1 Clinical Trials Search in Europe

Study on the Safety and Effectiveness of Vepdegestrant and PF-07220060 for Adults with ER+/HER2- Advanced or Metastatic Breast Cancer

1 1 1

What is this study about?

This clinical trial is focused on studying a type of breast cancer known as ER-positive/HER2-negative advanced or metastatic breast cancer. This type of cancer is characterized by the presence of estrogen receptors and the absence of human epidermal growth factor receptor 2. The study involves two medications: Vepdegestrant (ARV-471/PF-07850327) and PF-07220060. Vepdegestrant is an oral medication designed to target and break down specific proteins in cancer cells, while PF-07220060 is another oral medication being tested in combination with Vepdegestrant.

The purpose of the study is to evaluate the safety and effectiveness of these medications when used together. Participants will take the medications in the form of film-coated tablets. The study will be conducted in two phases. In the first phase, the focus will be on assessing how well participants tolerate the combination of medications and determining the best doses to use. In the second phase, the study will look at how effective the combination is in treating the cancer.

Throughout the study, participants will be monitored for any side effects and changes in their condition. The study aims to provide valuable information on the potential benefits of using Vepdegestrant and PF-07220060 together for treating this specific type of breast cancer. Participants will receive regular check-ups and assessments to track their progress and ensure their safety during the trial.

1 joining the study

Upon joining the study, eligibility is confirmed based on age, diagnosis of breast cancer, and previous treatments. Participants must be 18 years or older and have a diagnosis of advanced or metastatic breast cancer that cannot be surgically removed.

Participants must have received at least one line of standard care for advanced or metastatic breast cancer and meet specific criteria regarding previous therapies.

2 initial assessment

An initial assessment is conducted to evaluate the participant’s health status. This includes a review of medical history, physical examination, and laboratory tests.

The assessment ensures that participants have the required measurable lesions and meet the performance status criteria.

3 treatment phase 1b

Participants receive a combination of vepdegestrant and PF-07220060. The treatment is administered orally in the form of film-coated tablets.

The primary goal is to assess the safety and tolerability of the combination to determine the recommended dosage.

4 treatment phase 2

In this phase, the focus is on evaluating the antitumor activity of the treatment combination. Participants continue to receive the oral medication as determined in phase 1b.

The effectiveness of the treatment is assessed through regular monitoring of tumor response and overall health.

5 monitoring and follow-up

Throughout the trial, participants undergo regular monitoring, including blood tests, imaging studies, and assessments of side effects.

The trial aims to track the duration of response, clinical benefit, and progression-free survival.

6 completion of the trial

The trial is expected to conclude by March 2027. Participants will have a final assessment to evaluate the overall impact of the treatment.

Data collected will contribute to understanding the safety and efficacy of the treatment combination for advanced or metastatic breast cancer.

Who Can Join the Study?

  • Participants must be 18 years or older at the time of screening.
  • Must have a diagnosis of breast cancer that cannot be removed by surgery to cure it. The cancer must have 1% or more cells that are ER+ (estrogen receptor-positive) and HER2- (human epidermal growth factor receptor 2-negative) based on the most recent tumor biopsy.
  • Participants with breast cancer in both breasts that are ER+/HER2- are eligible.
  • A tumor sample collected at the time of diagnosis with local recurrent or metastatic disease or an archival tumor tissue is required for inclusion.
  • For Phase 1b: Participants should have received at least one line of standard treatment for advanced or metastatic breast cancer. Prior use of fulvestrant is allowed. No more than one prior chemotherapy line is allowed, and no antibody-drug conjugates are permitted.
  • For Phase 2: Participants must have had at least one and a maximum of two lines of hormone therapy for advanced or metastatic breast cancer, with the most recent hormone therapy lasting more than six months. They must have used one CDK4/6 inhibitor (a type of cancer treatment) in any setting. Up to one prior chemotherapy regimen is allowed, and no antibody-drug conjugates are permitted. Prior use of fulvestrant is allowed.
  • For Phase 1b: Participants with only non-measurable lesions (such as skin or bone lesions) are eligible.
  • For Phase 2: Participants must have at least one measurable lesion as defined by RECIST v1.1 (a standard way to measure cancer response to treatment). Participants with only bone lesions can be included if at least one bone lesion has a measurable component.
  • Participants must have an ECOG performance status of 0 or 1 for Phase 1b, and 0, 1, or 2 for Phase 2. This is a scale used to assess how a patient’s disease is progressing, including their ability to perform daily activities.

Who Cannot Join the Study?

  • Patients with other types of cancer besides advanced or metastatic breast cancer cannot participate. This means the cancer has spread to other parts of the body.
  • Patients who are not able to safely take the study medications due to other health conditions or medications they are currently taking.
  • Patients who are pregnant or breastfeeding are not eligible to participate.
  • Patients who have participated in another clinical trial within a certain period before this study may be excluded.
  • Patients with certain heart conditions or other serious medical issues that could interfere with the study.
  • Patients who have had a recent surgery or are planning to have surgery during the study period.
  • Patients who have an active infection or other illness that could affect their ability to participate in the study.
  • Patients who have a history of allergic reactions to similar medications used in the study.
  • Patients who are unable to follow the study procedures or attend the required visits.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Institut Gustave Roussy Villejuif France
Katholieke Universiteit te Leuven Leuven Belgium
Comite Entreprise Paul Papin Angers France

Other Sites

Site Name City Country Status
Institut Jules Bordet Anderlecht Belgium
Hospital Universitario 12 De Octubre Madrid Spain
Grand Hopital De Charleroi Charleroi Belgium
Algemeen Ziekenhuis Groeninge Kortrijk Belgium
Virgen del Rocío University Hospital Sevilla Spain
Hospital Universitari Arnau De Vilanova De La Gerencia Territorial De Lleida Lleida Spain
Iwtshouw Rfqhzhut Do Cwnbqn Dm Mcezzwvbfaq Montpellier France
Ubiytvmlcf Oa Agnmhxg Edegem Belgium
Hqwzprfe Voky dragqarw Barcelona Spain
Ilsrikaz Pskgpgplszwnjyz Cbvbdk Cfsqsw Marseille France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Not recruiting
14.02.2024
France France
Not recruiting
14.02.2024
Spain Spain
Not recruiting
14.02.2024

Trial locations

Investigated drugs:

Vepdegestrant (ARV-471/PF-07850327) is an oral medication being studied for its ability to target and degrade specific proteins involved in cancer growth. It is being tested for its safety and effectiveness in treating advanced or metastatic breast cancer that is positive for estrogen receptors (ER+) and negative for human epidermal growth factor receptor 2 (HER2-). This medication is part of a new class of treatments known as proteolysis targeting chimeras, which aim to break down proteins that contribute to cancer progression.

PF-07220060 is another medication being tested in combination with vepdegestrant. It is being studied for its potential to enhance the antitumor effects when used alongside vepdegestrant in patients with ER+/HER2- advanced or metastatic breast cancer. The goal is to determine if this combination can improve treatment outcomes by effectively targeting cancer cells.

Investigated diseases:

Advanced or Metastatic Breast Cancer – This is a stage of breast cancer where the disease has spread beyond the breast and nearby lymph nodes to other parts of the body. It often affects organs such as the bones, liver, lungs, or brain. The progression of this cancer can vary, with some individuals experiencing rapid spread while others may have a slower progression. Symptoms can include pain, fatigue, and other signs depending on the organs affected. The disease is characterized by its ability to evade initial treatments and continue growing. Management focuses on controlling the spread and alleviating symptoms.

Trial ID:
2023-508130-33-00
Protocol code:
C4891026
Trial Phase:
Human Pharmacology (Phase I) – Other

Other Trials to Consider

  • A study to test the safety and effectiveness of ONA-255 in patients with advanced cancer including breast cancer and gastric cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Spain

  • A Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain